Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Autolus Therapeutics Is Surging Today

By Cory Renauer – Aug 2, 2021 at 12:33PM

Key Points

  • Autolus Therapeutics signed an option and license agreement with Moderna for up to four immuno-oncology targets.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Potential licensing agreements with Moderna are giving investors reasons to cheer.

What happened

Shares of Autolus Therapeutics (AUTL 3.20%), a clinical-stage biopharmaceutical company, are on the move after the company announced a new deal with Moderna (MRNA 1.01%). Investors excited about Autolus Therapeutics' potential role in Moderna's commercialization of RNA-based therapeutics drove the stock more than 25% higher when the market opened, but the gains have subsided as investors pick apart the details. Autolus Therapeutics' stock price was 13% higher as of 11:18 a.m. EDT on Monday.

So what 

Autolus is developing a whole new class of reprogrammed T-cell therapies to treat cancer and not RNA-based drugs like Moderna. Under the terms of a new exclusive access agreement, though, Moderna could incorporate some of Autolus' proprietary binders into new cancer therapy candidates.

Scientist working under a fume hood.

Image source: Getty Images.

It appears Moderna wants to combine its RNA technology with Autolus' proprietary binders to train harvested T-cells to recognize and bind to targets found on cancer cells. All of Moderna's drug candidates rely on RNA, but RNA can spur dangerous inflammatory reactions that will keep its usage in new drugs limited to products that don't require repeat dosing. 

Now what

Granting larger drugmakers exclusive rights to license a new drug target is a big deal if your new partner is willing to pay a significant sum upfront for those rights. Autolus Therapeutics is eligible to receive payments each time Moderna actually licenses a new target, which hasn't happened yet. In other words, Autolus gave up its ability to retain ownership of up to four new cancer drug targets for the ability to tell investors it's partnered up with a big-name biotech company.

Autolus Therapeutics' lead candidate, AUTO1, is a CD19-directed CAR-T therapy that could be better than similar therapies that have been available since 2017. Instead of trying to follow it higher, it's probably best to tread lightly around this risky biotech stock for the foreseeable future.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Autolus Therapeutics Plc Stock Quote
Autolus Therapeutics Plc
AUTL
$2.58 (3.20%) $0.08
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$178.18 (1.01%) $1.78

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.